Immunology and inflammation

News

J&J gets FDA okay for psoriasis drug icotrokinra

Johnson & Johnson's much-anticipated oral IL-23 drug, icotrokinra, has claimed FDA approval as Icotyde for first-line treatment of plaque psoriasis.

News

Cancer risk scuppers Kyowa Kirin's autoimmune disease drug

Kyowa Kirin has terminated all clinical trials of its anti-OX40L antibody rocatinlimab, after cases of cancer were seen in patients taking the drug.

News

Boehringer bets up to $500m on Sitryx immunology programme

Boehringer Ingelheim's partnership with Sitryx is focused on a family of small-molecule drugs for autoimmune and inflammatory diseases.

News

Novartis' oral BTK drug moves the needle in CINDU

Novartis is set to expand the label for its oral BTK inhibitor Rhapsido, keeping the drug on course to become one of its biggest-ever brands.

News

Takeda signs $1.7bn AI alliance with Iambic

Iambic bags another pharma partner, Takeda, which plans to use its AI platform to find drugs for cancer, gastrointestinal, and inflammatory disorders.

News

Lilly strikes $8.8bn-plus alliance with China's Innovent

Eli Lilly has deepened its ties with Chinese biopharma company Innovent Biologics, signing a seventh R&D with a $350m upfront payment.

J&J gets FDA okay for psoriasis drug icotrokinra

Cancer risk scuppers Kyowa Kirin's autoimmune disease drug

Boehringer bets up to $500m on Sitryx immunology programme

Novartis' oral BTK drug moves the needle in CINDU

Takeda signs $1.7bn AI alliance with Iambic

Lilly strikes $8.8bn-plus alliance with China's Innovent

LSX2026: Non-opioid pain relief and pharma positivity, with ...

Using AI-driven synthetic personas to take your insights fur...

Immunology and inflammation

Editor's Picks